raloxifene has been researched along with tamoxifen in 35 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (2.86) | 18.7374 |
1990's | 5 (14.29) | 18.2507 |
2000's | 8 (22.86) | 29.6817 |
2010's | 16 (45.71) | 24.3611 |
2020's | 5 (14.29) | 2.80 |
Authors | Studies |
---|---|
Blaszczak, LC; Crowell, TA; Goettel, ME; Jones, CD; Mabry, TE; Ruenitz, PC; Srivatsan, V; Suarez, T | 1 |
Black, LJ; Clemens, JA; Falcone, JF; Jevnikar, MG; Jones, CD; Peters, MK; Pike, AJ; Thompson, AR | 1 |
Adrian, MD; Bryant, HU; Cho, S; Cole, HW; Finley, DR; Glasebrook, AL; Godfrey, AG; Grese, TA; Jones, CD; Lugar, CW; Magee, DE; Martin, MJ; Matsumoto, K; Pennington, LD; Phillips, DL; Rowley, ER; Short, LL; Winter, MA | 1 |
Carlsson, B; Enmark, E; Grandien, K; Gustafsson, JA; Häggblad, J; Kuiper, GG; Nilsson, S | 1 |
Adrian, MD; Bryant, HU; Cole, HW; Fuson, TR; Glasebrook, AL; Grese, TA; Magee, DE; Pennington, LD; Phillips, DL; Rowley, ER; Sato, M; Shetler, PK; Short, LL; Sluka, JP; Venugopalan, M; Yang, NN | 1 |
Glasebrook, AL; Misner, JW; Schmid, CR; Stephenson, GA | 1 |
Bischoff, SF; Buhl, T; Floersheim, P; Fournier, B; Halleux, C; Kallen, J; Keller, H; Renaud, J; Schlaeppi, JM; Stark, W | 1 |
Ikeno, A; Kohayakawa, C; Minato, H; Nakagawa, H; Tsuji, J; Watanabe, N | 1 |
Bischoff, SF; Buhl, T; Floersheim, P; Fournier, B; Geiser, M; Halleux, C; Kallen, J; Keller, H; Ramage, P; Renaud, J | 1 |
Fiechtner, B; Glossmann, H; Hoffmann, RD; Laggner, C; Langer, T; Moebius, FF; Poles, G; Schieferer, C | 1 |
Dansette, PM; Fontana, E; Poli, SM | 1 |
Bilter, GK; Dias, J; Huang, Z; Keon, BH; Lamerdin, J; MacDonald, ML; Michnick, SW; Minami, T; Owens, S; Shang, Z; Westwick, JK; Yu, H | 1 |
Armstrong, MD; Arteaga, CL; Brown, HA; Buck, JR; Cho, HP; Criswell, TL; Lindsley, CW; Scott, SA; Selvy, PE; Thomas, AL | 1 |
Allan, G; Cousineau, M; Du, F; Hahn, D; Jain, N; Jian-Zhong, G; Kanojia, RM; Lai, MT; Li, X; Lundeen, S; Musto, A; Pacia, E; Peng, S; Reuman, M; Ritchie, D; Russell, R; Sui, Z; Xu, J | 1 |
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
Dettmann, S; Gust, R; Müller, CE; Schiedel, A; Szymanowitz, K; Wellner, A | 1 |
Jain, D; Koh, JT | 1 |
Ekins, S; Williams, AJ; Xu, JJ | 1 |
Chang, FR; Chen, GY; Hayashi, K; Hsieh, CJ; Korinek, M; Lai, WC; Nozaki, H; Wang, HC; Wu, CC; Wu, YC; Yang, JC | 1 |
Bid, H; Chakravarti, B; Chattopadhyay, N; Dwivedi, A; Gupta, LP; Konwar, R; Kumar, A; Kumar, P; Nayak, VL; Saxena, R; Siddiquee, MI; Siddiqui, JA; Siddiqui, U; Tripathi, VD; Trivedi, R | 1 |
Hajjo, R; Roth, BL; Setola, V; Tropsha, A | 1 |
Bryant, HU; Chalmers, MJ; Dodge, JA; Griffin, PR; Montrose-Rafizdeh, C; Novick, S; Sato, M; Wang, Y | 1 |
Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
Brown, HA; Brown, KA; Cho, CH; Jung, DI; Larock, RC; Lavieri, RR; Lindsley, CW; O'Reilly, MC; Scott, SA; Spencer, CT | 1 |
Balogh, I; Kim, HY; Koczok, K; Korade, Z; Liu, W; Mirnics, K; Porter, NA; Tallman, KA; Xu, L | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Dandriyal, J; Jaitak, V; Kumar, M; Singla, R | 1 |
Lao, K; Li, X; Luo, G; Tang, Z; Xiang, H; You, Q | 1 |
Cai, X; Li, X; Lin, X; Liu, L; Luo, G; Wu, C; Xiang, H; You, Q | 1 |
Chen, H; Dubrovyskyii, O; Dye, K; Gordon-Blake, J; Gutgesell, LM; He, D; Hollas, M; Huang, F; Lasek, AW; Lee, S; Li, Y; Lu, Y; Rosales, CI; Shen, Z; Thatcher, GRJ; Tonetti, DA; Wang, Y; Xiong, R; Zhao, H; Zhao, J | 1 |
Anantpadma, M; Cheng, H; Cooper, L; Davey, RA; Dye, K; Li, Y; Medegan Fagla, B; Nowar, R; Rong, L; Schafer, A; Shen, Z; Thatcher, GRJ; Xiong, R | 1 |
Aljondi, B; Balakin, KV; Bondar, OV; Bulatov, TM; Gabbasova, RR; Grishaev, DY; Iksanova, AG; Kataeva, ON; Nguyen, TNT; Nikishova, TV; Pavelyev, RS; Pugachev, MV; Shtyrlin, YG; Yamaleeva, ZR | 1 |
Bai, C; Luo, G; Ren, S; Wu, S; Xiang, H; Zhu, M | 2 |
Ahmad, S; Ejaz, I; Ikram, M; Jan, MS; Javed, MA; Rashid, U; Sadiq, A | 1 |
3 review(s) available for raloxifene and tamoxifen
Article | Year |
---|---|
Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.
Topics: Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Enzyme Inhibitors; Humans; Isoenzymes; Structure-Activity Relationship; Terminology as Topic | 2005 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Recent developments of C-4 substituted coumarin derivatives as anticancer agents.
Topics: Animals; Antineoplastic Agents; Coumarins; Humans | 2016 |
32 other study(ies) available for raloxifene and tamoxifen
Article | Year |
---|---|
Antiestrogens. 3. Estrogen receptor affinities and antiproliferative effects in MCF-7 cells of phenolic analogues of trioxifene, [3,4-dihydro-2-(4- methoxyphenyl)-1-naphthalenyl][4-[2-(1-pyrrolidinyl)ethoxy]- phenyl]methanone.
Topics: Antineoplastic Agents; Binding, Competitive; Breast Neoplasms; Calmodulin; Cell Division; Estradiol; Estrogen Antagonists; Humans; Molecular Structure; Phenols; Pyrrolidines; Receptors, Estrogen; Tamoxifen; Tumor Cells, Cultured | 1992 |
Antiestrogens. 2. Structure-activity studies in a series of 3-aroyl-2-arylbenzo[b]thiophene derivatives leading to [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl] [4-[2-(1-piperidinyl)ethoxy]-phenyl]methanone hydrochloride (LY156758), a remarkably effec
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Estrogen Antagonists; Female; Mammary Neoplasms, Experimental; Piperidines; Raloxifene Hydrochloride; Rats; Receptors, Estrogen; Structure-Activity Relationship; Uterus | 1984 |
Structure-activity relationships of selective estrogen receptor modulators: modifications to the 2-arylbenzothiophene core of raloxifene.
Topics: Adenocarcinoma; Animals; Binding Sites; Bone and Bones; Breast Neoplasms; Cell Division; Cholesterol; Estrogen Antagonists; Female; Humans; Male; Organ Size; Ovariectomy; Piperidines; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Receptors, Estrogen; Structure-Activity Relationship; Uterus | 1997 |
Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta.
Topics: Amino Acid Sequence; Animals; Female; Humans; Isomerism; Ligands; Male; Molecular Sequence Data; Rats; Receptors, Estrogen; RNA, Messenger; Tissue Distribution | 1997 |
Synthesis and pharmacology of conformationally restricted raloxifene analogues: highly potent selective estrogen receptor modulators.
Topics: Animals; Bone Density; Cell Division; Cholesterol; Estrogen Antagonists; Female; Gene Expression Regulation; HeLa Cells; Humans; Models, Molecular; Molecular Conformation; Naphthoquinones; Organ Size; Ovariectomy; Piperidines; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Receptors, Estrogen; Structure-Activity Relationship; Transforming Growth Factor beta; Tumor Cells, Cultured; Uterus | 1998 |
Synthesis and biological activity of trans-2,3-dihydroraloxifene.
Topics: Binding, Competitive; Cell Division; Dose-Response Relationship, Drug; Estrogen Antagonists; Models, Molecular; Piperidines; Raloxifene Hydrochloride; Tumor Cells, Cultured | 1999 |
Estrogen receptor modulators: identification and structure-activity relationships of potent ERalpha-selective tetrahydroisoquinoline ligands.
Topics: Administration, Oral; Animals; Binding Sites; Biological Availability; Cell Division; Crystallography, X-Ray; Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogen Receptor Modulators; Female; HeLa Cells; Humans; Isoquinolines; Ligands; Models, Molecular; Radioligand Assay; Raloxifene Hydrochloride; Rats; Receptors, Estrogen; Stereoisomerism; Structure-Activity Relationship; Transcription, Genetic; Tumor Cells, Cultured | 2003 |
4-(4-alkylpiperazin-1-yl)phenyl group: a novel class of basic side chains for selective estrogen receptor modulators.
Topics: Alkanes; Animals; Cholesterol; Female; Humans; Kinetics; Models, Molecular; Molecular Conformation; Piperazines; Rats; Receptors, Estrogen; Structure-Activity Relationship; Uterus | 2003 |
Selective estrogen receptor modulators with conformationally restricted side chains. Synthesis and structure-activity relationship of ERalpha-selective tetrahydroisoquinoline ligands.
Topics: Animals; Biological Availability; Cell Line, Tumor; Crystallography, X-Ray; Drug Screening Assays, Antitumor; Estrogen Receptor alpha; Female; Humans; Inhibitory Concentration 50; Isoquinolines; Ligands; Models, Molecular; Piperazines; Piperidines; Radioligand Assay; Rats; Selective Estrogen Receptor Modulators; Structure-Activity Relationship; Tetrahydroisoquinolines | 2005 |
Discovery of high-affinity ligands of sigma1 receptor, ERG2, and emopamil binding protein by pharmacophore modeling and virtual screening.
Topics: Animals; Carrier Proteins; Databases, Factual; Guinea Pigs; Humans; Hydrogen Bonding; Hydrophobic and Hydrophilic Interactions; Isomerism; Ligands; Models, Molecular; Quantitative Structure-Activity Relationship; Radioligand Assay; Receptors, sigma; Saccharomyces cerevisiae; Sigma-1 Receptor; Steroid Isomerases | 2005 |
Identifying off-target effects and hidden phenotypes of drugs in human cells.
Topics: Bacterial Proteins; Cell Line; Cell Proliferation; Cluster Analysis; Drug Design; Drug Evaluation, Preclinical; Genetics; Humans; Luminescent Proteins; Molecular Structure; Phenotype; Recombinant Fusion Proteins; Signal Transduction; Structure-Activity Relationship | 2006 |
Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness.
Topics: Breast Neoplasms; Drug Design; Enzyme Inhibitors; Humans; Isoenzymes; Neoplasm Invasiveness; Phospholipase D | 2009 |
Identification and structure-activity relationships of chromene-derived selective estrogen receptor modulators for treatment of postmenopausal symptoms.
Topics: Animals; Benzopyrans; Bone Resorption; Cell Line, Tumor; Cholesterol; Drug Evaluation, Preclinical; Drug Stability; Epithelial Cells; Female; Hot Flashes; Humans; Organ Size; Ovariectomy; Postmenopause; Rats; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Structure-Activity Relationship; Substrate Specificity; Uterus; Vagina | 2009 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
2-phenyl-1-[4-(2-piperidine-1-yl-ethoxy)benzyl]-1H-benzimidazoles as ligands for the estrogen receptor: synthesis and pharmacological evaluation.
Topics: Antineoplastic Agents; Benzimidazoles; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Estrogen Receptor beta; Female; Gene Expression Regulation, Neoplastic; Humans | 2010 |
A mutant selective anti-estrogen is a pure antagonist on EREs and AP-1 response elements.
Topics: Estrogen Receptor Modulators; Mutation; Receptors, Estrogen; Transcription Factor AP-1 | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Using the pER8:GUS reporter system to screen for phytoestrogens from Caesalpinia sappan.
Topics: Arabidopsis; Caesalpinia; Chromones; Drug Screening Assays, Antitumor; Drugs, Chinese Herbal; Estradiol; Estrogens; Female; Genistein; Hep G2 Cells; Humans; Models, Molecular; Molecular Structure; Phytoestrogens; Plants, Genetically Modified; Selective Estrogen Receptor Modulators; Taiwan; Wood | 2011 |
Design and synthesis of 1,3-biarylsulfanyl derivatives as new anti-breast cancer agents.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Female; HEK293 Cells; Humans; Models, Molecular; Molecular Conformation; Stereoisomerism; Structure-Activity Relationship; Sulfhydryl Compounds | 2011 |
Chemocentric informatics approach to drug discovery: identification and experimental validation of selective estrogen receptor modulators as ligands of 5-hydroxytryptamine-6 receptors and as potential cognition enhancers.
Topics: Alzheimer Disease; Cell Line, Tumor; Cloning, Molecular; Cognition; Drug Discovery; Drug Evaluation, Preclinical; Genomics; Humans; Informatics; Ligands; Nootropic Agents; Quantitative Structure-Activity Relationship; Raloxifene Hydrochloride; Receptors, Serotonin; Reproducibility of Results; Selective Estrogen Receptor Modulators; Serotonin Antagonists; User-Computer Interface | 2012 |
Hydrophobic Interactions Improve Selectivity to ERα for Ben-zothiophene SERMs.
Topics: | 2012 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Discovery of desketoraloxifene analogues as inhibitors of mammalian, Pseudomonas aeruginosa, and NAPE phospholipase D enzymes.
Topics: Animals; Cell Line; Enzyme Inhibitors; Gene Expression Regulation, Enzymologic; Humans; Molecular Structure; Phospholipase D; Pseudomonas aeruginosa; Raloxifene Hydrochloride | 2015 |
The Effect of Small Molecules on Sterol Homeostasis: Measuring 7-Dehydrocholesterol in Dhcr7-Deficient Neuro2a Cells and Human Fibroblasts.
Topics: Animals; Cell Line; Dehydrocholesterols; Dose-Response Relationship, Drug; Fibroblasts; Homeostasis; Humans; Mice; Molecular Conformation; Neurons; Oxidoreductases Acting on CH-CH Group Donors; Small Molecule Libraries; Sterols; Structure-Activity Relationship | 2016 |
Structure-activity relationships of 2, 4-disubstituted pyrimidines as dual ERα/VEGFR-2 ligands with anti-breast cancer activity.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Estrogen Receptor alpha; Female; Humans; Ligands; MCF-7 Cells; Molecular Structure; Neovascularization, Pathologic; Pyrimidines; Structure-Activity Relationship; Vascular Endothelial Growth Factor Receptor-2 | 2018 |
Synthesis and biological evaluation of 3-aryl-quinolin derivatives as anti-breast cancer agents targeting ERα and VEGFR-2.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Cycle; Cell Movement; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Estrogen Receptor alpha; Female; Humans; Molecular Structure; Protein Kinase Inhibitors; Quinolines; Structure-Activity Relationship; Vascular Endothelial Growth Factor Receptor-2 | 2019 |
Design and Synthesis of Basic Selective Estrogen Receptor Degraders for Endocrine Therapy Resistant Breast Cancer.
Topics: Animals; Apoptosis; Aromatase Inhibitors; Breast Neoplasms; Cell Proliferation; Drug Design; Drug Resistance, Neoplasm; Estrogen Receptor alpha; Female; Humans; Mice; Mice, Inbred C57BL; Mice, Nude; Mutation; Proteolysis; Rats; Rats, Sprague-Dawley; Selective Estrogen Receptor Modulators; Thiophenes; Tissue Distribution; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2019 |
Screening and Reverse-Engineering of Estrogen Receptor Ligands as Potent Pan-Filovirus Inhibitors.
Topics: Antiviral Agents; Cell Line, Tumor; Drug Evaluation, Preclinical; Filoviridae; Humans; Ligands; Membrane Fusion; Models, Biological; Receptors, Estrogen; Structure-Activity Relationship | 2020 |
Synthesis, antitumor activity and structure-activity studies of novel pyridoxine-based bioisosteric analogs of estradiol.
Topics: Antineoplastic Agents; Cell Proliferation; Crystallography, X-Ray; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Estradiol; Humans; Membrane Potential, Mitochondrial; Models, Molecular; Molecular Structure; Pyridoxine; Reactive Oxygen Species; Structure-Activity Relationship; Tumor Cells, Cultured | 2021 |
Design and synthesis of novel benzothiophene analogs as selective estrogen receptor covalent antagonists against breast cancer.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Estrogen Receptor Antagonists; Female; Humans; MCF-7 Cells; Molecular Structure; Receptors, Estrogen; Structure-Activity Relationship; Thiophenes; Tumor Cells, Cultured | 2021 |
Benzothiophene derivatives as selective estrogen receptor covalent antagonists: Design, synthesis and anti-ERα activities.
Topics: Dose-Response Relationship, Drug; Drug Design; Estrogen Antagonists; Estrogen Receptor alpha; Humans; Molecular Structure; Structure-Activity Relationship; Thiophenes | 2021 |
Rational design, synthesis, antiproliferative activity against MCF-7, MDA-MB-231 cells, estrogen receptors binding affinity, and computational study of indenopyrimidine-2,5-dione analogs for the treatment of breast cancer.
Topics: Breast Neoplasms; Cell Proliferation; Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Female; HEK293 Cells; Humans; MCF-7 Cells; Receptors, Estrogen | 2022 |